Sangamo Shares Plunge After Pfizer Ends Gene Therapy Deal
Sangamo stock drops sharply as Pfizer terminates collaboration on hemophilia A gene therapy. Explore the impact on Sangamo's market position and future plans.
Sangamo stock fell significantly after Pfizer ended their collaboration on a gene therapy for hemophilia A.